NZ572756A - Deimmunized antagonistic anti-human cd40 monoclonal antibody from the ch5d12 antibody - Google Patents
Deimmunized antagonistic anti-human cd40 monoclonal antibody from the ch5d12 antibodyInfo
- Publication number
- NZ572756A NZ572756A NZ572756A NZ57275607A NZ572756A NZ 572756 A NZ572756 A NZ 572756A NZ 572756 A NZ572756 A NZ 572756A NZ 57275607 A NZ57275607 A NZ 57275607A NZ 572756 A NZ572756 A NZ 572756A
- Authority
- NZ
- New Zealand
- Prior art keywords
- antibody
- human
- deimmunized
- ch5d12
- antagonistic anti
- Prior art date
Links
- 230000003042 antagnostic effect Effects 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US79881906P | 2006-05-09 | 2006-05-09 | |
| EP06076028A EP1854810A1 (en) | 2006-05-09 | 2006-05-09 | Deimmunized antagonistic anti-human CD40 monoclonal antibody from the ch5D12 antibody |
| PCT/NL2007/050202 WO2007129895A2 (en) | 2006-05-09 | 2007-05-09 | Deimmunized antagonistic anti-human cd40 monoclonal antibody from the ch5d12 antibody |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ572756A true NZ572756A (en) | 2012-10-26 |
Family
ID=37635851
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ572756A NZ572756A (en) | 2006-05-09 | 2007-05-09 | Deimmunized antagonistic anti-human cd40 monoclonal antibody from the ch5d12 antibody |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US8669352B2 (enExample) |
| EP (2) | EP1854810A1 (enExample) |
| JP (1) | JP5179474B2 (enExample) |
| KR (1) | KR101506348B1 (enExample) |
| CN (1) | CN101490086B (enExample) |
| AR (1) | AR060998A1 (enExample) |
| AU (1) | AU2007249031B9 (enExample) |
| BR (1) | BRPI0711355A2 (enExample) |
| CA (1) | CA2651565A1 (enExample) |
| CL (1) | CL2007001335A1 (enExample) |
| DK (1) | DK2019840T3 (enExample) |
| ES (1) | ES2406163T3 (enExample) |
| IL (1) | IL195196A (enExample) |
| MX (1) | MX2008014304A (enExample) |
| NO (1) | NO20085104L (enExample) |
| NZ (1) | NZ572756A (enExample) |
| RU (1) | RU2491295C2 (enExample) |
| TW (1) | TWI455947B (enExample) |
| WO (1) | WO2007129895A2 (enExample) |
| ZA (2) | ZA200810381B (enExample) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2826788B1 (en) | 2006-06-21 | 2017-12-13 | MUSC Foundation for Research Development | Targeting complement factor h for treatment of diseases by the use of cr2-fh molecules |
| WO2011003098A1 (en) | 2009-07-02 | 2011-01-06 | Musc Foundation For Research Development | Methods of stimulating liver regeneration |
| PT2462158T (pt) | 2009-08-06 | 2018-02-23 | H Hoffnabb La Roche Ag | Método para melhorar a remoção de vírus na purificação de proteínas |
| US10239937B2 (en) | 2009-11-05 | 2019-03-26 | Alexion Pharmaceuticals, Inc. | Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis |
| WO2011109280A1 (en) | 2010-03-05 | 2011-09-09 | Lerner Research Institute | Methods and compositions to treat immune-mediated disorders |
| SG183947A1 (en) * | 2010-03-31 | 2012-10-30 | Boehringer Ingelheim Int | Anti-cd40 antibodies |
| SG185483A1 (en) | 2010-05-14 | 2012-12-28 | Univ Colorado Regents | Improved complement receptor 2 (cr2) targeting groups |
| MX2012014975A (es) | 2010-06-22 | 2013-03-12 | Univ Colorado Regents | Anticuerpos al fragmento c3d de componente 3 de complemento. |
| AR083847A1 (es) | 2010-11-15 | 2013-03-27 | Novartis Ag | Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40 |
| WO2012125569A2 (en) | 2011-03-11 | 2012-09-20 | Beth Israel Deaconess Medical Center, Inc. | Anti-cd40 antibodies and uses thereof |
| TWI598363B (zh) | 2011-04-21 | 2017-09-11 | 必治妥美雅史谷比公司 | 拮抗ｃｄ４０之抗體多肽 |
| SMT202000091T1 (it) | 2011-10-13 | 2020-05-08 | Bristol Myers Squibb Co | Polipeptidi anticorpali che antagonizzano cd40l |
| AU2013302441B2 (en) | 2012-08-17 | 2018-05-10 | The Regents Of The University Of Colorado, A Body Corporate | Compositions and methods for detecting complement activation |
| US10413620B2 (en) | 2012-08-17 | 2019-09-17 | The Regents Of The University Of Colorado, A Body Corporate | Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging |
| WO2014200349A1 (en) | 2013-06-13 | 2014-12-18 | Fast Forward Pharmaceutical B.V. | Cd40 signalling inhibitor and a further compound, wherein the further compound is a bile acid, a bile acid derivative, an tgr5-receptor agonist, an fxr agonist or a combination thereof, for the treatment of chronic inflammation, and the prevention of gastrointestinal cancer or fibrosis. |
| EP2883883A1 (en) | 2013-12-16 | 2015-06-17 | Cardio3 Biosciences S.A. | Therapeutic targets and agents useful in treating ischemia reperfusion injury |
| US10435475B2 (en) | 2014-03-07 | 2019-10-08 | Bristol-Myers Squibb Company | Method of using antibody polypeptides that antagonize CD40 to treat IBD |
| PL3178931T3 (pl) * | 2014-08-07 | 2021-06-14 | Daiichi Sankyo Company, Limited | Przeciwciało anty-orai1 |
| US20170233485A1 (en) * | 2014-08-18 | 2017-08-17 | Biogen Ma Inc. | Anti-cd40 antibodies and uses thereof |
| KR102656470B1 (ko) | 2014-12-10 | 2024-04-09 | 리전츠 오브 더 유니버스티 오브 미네소타 | 질환을 치료하기 위한 유전적으로 변형된 세포, 조직 및 장기 |
| UY36692A (es) | 2015-05-29 | 2016-12-30 | Abbvie Inc | Anticuerpos anti-cd40 y usos de los mismos |
| SI3307322T1 (sl) | 2015-09-04 | 2021-08-31 | Primatope Therapeutics Inc. | Humanizirana protitelesa proti CD40 in njihove uporabe |
| MA43053A (fr) | 2015-09-30 | 2018-08-08 | Janssen Biotech Inc | Anticorps antagonistes se liant spécifiquement au cd40 humain et procédés d'utilisation |
| WO2017220989A1 (en) | 2016-06-20 | 2017-12-28 | Kymab Limited | Anti-pd-l1 and il-2 cytokines |
| CN110382541A (zh) * | 2017-03-29 | 2019-10-25 | 葛莱高托普有限公司 | 人源化抗cd40抗体 |
| JP7257971B6 (ja) | 2017-06-01 | 2023-07-24 | 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 | 抗ｃｄ４０抗体、その抗原結合フラグメント、およびその医学的使用 |
| WO2019087094A1 (en) | 2017-11-03 | 2019-05-09 | Novartis Ag | Anti-cd40 antibodies for use in treatment of sjögren's syndrome |
| WO2019156565A1 (en) | 2018-02-12 | 2019-08-15 | Fast Forward Pharmaceuticals B.V. | Improved antagonistic anti-human cd40 monoclonal antibodies |
| BR112020020277A2 (pt) | 2018-04-13 | 2021-01-19 | Novartis Ag | Anticorpos anti-cd40 para uso na prevenção de rejeição de enxerto |
| AU2019255781A1 (en) * | 2018-04-20 | 2020-10-29 | Lyvgen Biopharma Holdings Limited | Anti-CD40 antibodies and uses thereof |
| KR20210035805A (ko) | 2018-06-15 | 2021-04-01 | 플래그쉽 파이어니어링 이노베이션스 브이, 인크. | 세포후 신호전달 인자의 조절을 통한 면역 활성의 증가 |
| KR20210070317A (ko) | 2018-09-28 | 2021-06-14 | 리브젠 바이오파마 코., 엘티디. | 조작된 Fc 도메인을 갖는 항-CD40 결합 분자 및 그의 치료적 용도 |
| EP3860653A1 (en) | 2018-10-05 | 2021-08-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and systems for controlling the agonistic properties of antibody variable domains by light |
| WO2020102454A1 (en) | 2018-11-13 | 2020-05-22 | Regents Of The University Of Minnesota | Cd40 targeted peptides and uses thereof |
| CN112839961B (zh) | 2018-11-30 | 2023-04-04 | 江苏恒瑞医药股份有限公司 | 一种cd40抗体药物组合物及其用途 |
| MX2021005823A (es) | 2018-11-30 | 2021-07-15 | Jiangsu Hengrui Medicine Co | Anticuerpo anti-cd40, fragmento de union a antigeno y uso farmaceutico del mismo. |
| US12435150B2 (en) | 2019-01-11 | 2025-10-07 | Novartis Ag | Anti-CD40 antibodies for use in treatment of hidradenitis suppurativa |
| EP3962493A2 (en) | 2019-05-03 | 2022-03-09 | Flagship Pioneering Innovations V, Inc. | Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor |
| KR20220007086A (ko) | 2019-05-08 | 2022-01-18 | 노파르티스 아게 | T1dm 및 췌도염의 치료에 사용하기 위한 항-cd40 항체 |
| JP2022553493A (ja) | 2019-09-11 | 2022-12-23 | ノバルティス アーゲー | 患者におけるヒトウイルス関連障害を予防するための方法 |
| US20230114107A1 (en) | 2019-12-17 | 2023-04-13 | Flagship Pioneering Innovations V, Inc. | Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly |
| JP2023532339A (ja) | 2020-06-29 | 2023-07-27 | フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド | サノトランスミッションを促進するためにエンジニアリングされたウイルス及び癌の処置におけるそれらの使用 |
| SI4284512T1 (sl) | 2021-01-28 | 2025-06-30 | Regeneron Pharmaceuticals, Inc. | Sestavki in postopki za zdravljenje sindroma sproščanja citokinov |
| JP2024512669A (ja) | 2021-03-31 | 2024-03-19 | フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド | タノトランスミッションポリペプチド及び癌の処置におけるそれらの使用 |
| CA3224374A1 (en) | 2021-06-29 | 2023-01-05 | Flagship Pioneering Innovations V, Inc. | Immune cells engineered to promote thanotransmission and uses thereof |
| WO2023020475A1 (en) * | 2021-08-16 | 2023-02-23 | Utc Therapeutics (Shanghai) Co., Ltd. | Cd40-targetting antibodies and uses thereof |
| US20250002527A1 (en) | 2021-08-26 | 2025-01-02 | Duality Biologics (Suzhou) Co., Ltd. | Steroid compound and conjugate thereof |
| US12234294B2 (en) | 2021-11-05 | 2025-02-25 | Kiniksa Pharmaceuticals, Gmbh | Pharmaceutical composition of a humanized anti-CD40 antibody |
| WO2023198851A1 (en) | 2022-04-14 | 2023-10-19 | Institut National de la Santé et de la Recherche Médicale | Methods for controlling the tumor cell killing by light |
| WO2024077191A1 (en) | 2022-10-05 | 2024-04-11 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer |
| WO2024151687A1 (en) | 2023-01-09 | 2024-07-18 | Flagship Pioneering Innovations V, Inc. | Genetic switches and their use in treating cancer |
| US20250277048A1 (en) | 2024-03-01 | 2025-09-04 | Regeneron Pharmaceuticals, Inc. | The use of cd40 inhibitors for inhibiting an immune response and enabling immunogen administration and re-administration |
| US20250276092A1 (en) | 2024-03-01 | 2025-09-04 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9125768D0 (en) | 1991-12-04 | 1992-02-05 | Hale Geoffrey | Therapeutic method |
| US5874082A (en) | 1992-07-09 | 1999-02-23 | Chiron Corporation | Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation |
| EP0651797B1 (en) | 1992-07-09 | 2004-01-28 | Chiron Corporation | A method for generation of antibodies to cell surface molecules |
| JP4219985B2 (ja) | 1996-07-23 | 2009-02-04 | タノックス ファーマ ベスローテン フェンノートシャップ | 二つの共刺激経路を同時にブロックできる可溶性分子を用いたｔ細胞寛容の誘導 |
| GB2339430A (en) * | 1997-05-21 | 2000-01-26 | Biovation Ltd | Method for the production of non-immunogenic proteins |
| US6051228A (en) * | 1998-02-19 | 2000-04-18 | Bristol-Myers Squibb Co. | Antibodies against human CD40 |
| AR039067A1 (es) * | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
| US7563443B2 (en) * | 2004-09-17 | 2009-07-21 | Domantis Limited | Monovalent anti-CD40L antibody polypeptides and compositions thereof |
-
2006
- 2006-05-09 EP EP06076028A patent/EP1854810A1/en not_active Withdrawn
-
2007
- 2007-05-09 US US11/801,344 patent/US8669352B2/en active Active
- 2007-05-09 BR BRPI0711355-2A patent/BRPI0711355A2/pt not_active IP Right Cessation
- 2007-05-09 KR KR1020087030080A patent/KR101506348B1/ko active Active
- 2007-05-09 AR ARP070102017A patent/AR060998A1/es not_active Application Discontinuation
- 2007-05-09 CN CN200780025878.9A patent/CN101490086B/zh active Active
- 2007-05-09 TW TW096116566A patent/TWI455947B/zh not_active IP Right Cessation
- 2007-05-09 CA CA002651565A patent/CA2651565A1/en not_active Abandoned
- 2007-05-09 WO PCT/NL2007/050202 patent/WO2007129895A2/en not_active Ceased
- 2007-05-09 ES ES07747426T patent/ES2406163T3/es active Active
- 2007-05-09 AU AU2007249031A patent/AU2007249031B9/en active Active
- 2007-05-09 NZ NZ572756A patent/NZ572756A/xx not_active IP Right Cessation
- 2007-05-09 EP EP07747426A patent/EP2019840B1/en active Active
- 2007-05-09 DK DK07747426.0T patent/DK2019840T3/da active
- 2007-05-09 JP JP2009509467A patent/JP5179474B2/ja active Active
- 2007-05-09 CL CL2007001335A patent/CL2007001335A1/es unknown
- 2007-05-09 ZA ZA200810381A patent/ZA200810381B/xx unknown
- 2007-05-09 MX MX2008014304A patent/MX2008014304A/es active IP Right Grant
- 2007-05-09 RU RU2008148303/10A patent/RU2491295C2/ru not_active IP Right Cessation
-
2008
- 2008-11-10 IL IL195196A patent/IL195196A/en active IP Right Grant
- 2008-12-09 NO NO20085104A patent/NO20085104L/no not_active Application Discontinuation
-
2009
- 2009-12-23 ZA ZA2009/09185A patent/ZA200909185B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ572756A (en) | Deimmunized antagonistic anti-human cd40 monoclonal antibody from the ch5d12 antibody | |
| IL187594A0 (en) | Humanized anti-cd40 antibodies and their methods of use | |
| UA94452C2 (ru) | Гуманизированные моноклональные антитела к фактору роста гепатоцитов | |
| HRP20181459T1 (hr) | Humanizirani antagonisti anti-beta7 i njihove uporabe | |
| TW200639182A (en) | Antibody variants and uses thereof | |
| HRP20181565T1 (hr) | Monoklonska protutijela protiv klaudina-18 za liječenje karcinoma | |
| NO20071436L (no) | Humaniserte Anti-5T4 antistoffer og Anti-5T4 antistoff/calicheamicin konjugater | |
| WO2006099141A3 (en) | Anti-mesothelin antibodies | |
| IL212633A (en) | A monoclonal antibody or its antigen-binding portion, its pharmaceutical preparations and its use in the preparation of cancer drugs | |
| CY1111622T1 (el) | Ανθρωποποιημενοι ανταγωνιστες anti-cmet | |
| IL184152A (en) | Monoclonal antibodies against nkg2a, preparations containing them, their use in drug preparation, methods of manufacture, and methods used in | |
| MX2010002248A (es) | Anticuerpos anti-epha2. | |
| NZ597531A (en) | Inhibition of tumor metastasis using bv8- or g-csf-antagonists | |
| MX2009009926A (es) | Anticuerpo tumor-especifico humano monoclonal. | |
| WO2008042941A3 (en) | Humanized anti-ephb4 antibodies and their use in treatment of oncology and vasculogenesis-related disease | |
| WO2007033140A3 (en) | Prok2 antagonists and methods of use | |
| EP1813668A4 (en) | HYBRIDOM capable of producing a monoclonal anti-DECTIN-1 antibody |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 09 MAY 2014 BY DENNEMEYER SA Effective date: 20130418 |
|
| ASS | Change of ownership |
Owner name: FAST FORWARD PHARMACEUTICALS B.V., NL Effective date: 20130705 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 09 MAY 2017 BY DENNEMEYER SA Effective date: 20140417 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 MAY 2018 BY DENNEMEYER + CO Effective date: 20170426 |
|
| LAPS | Patent lapsed |